Abstract Meta-analysis is a technique for combining evidence from multiple trials. However, meta-analyses of studies with substantial heterogeneity among patients within trials-common in intensive carecan lead to incorrect conclusions if performed using aggregate data. Use of individual patient data (IPD) can avoid this concern, increase the power of a meta-analysis, and is useful for exploring subgroup effects. Barriers exist to IPD meta-analysis, most of which are overcome if clinical trials are designed to prospectively facilitate the incorporation of their results with other trials. We review the features of prospective IPD meta-analysis and identify those of relevance to intensive care research. We identify three clinical questions, which are the subject of recent or planned randomised controlled trials where IPD MA offers advantages over approaches using aggregate data.
Introduction
The most robust evidence for practice recommendations comes from adequately powered, multicentre randomised controlled trials (RCTs). Most RCTs rely on strict inclusion and exclusion criteria and treatment protocols in order to detect a treatment signal. This approach can make the delivery context of the new treatment unrepresentative of the ''real world''. Specifically, factors such as unit size, admission criteria, referral base, and what constitutes 'intensive care' differ markedly among sites and regions [1] . In intensive care, the context into which an intervention is delivered may be as influential as the intervention itself: for example, protocols for the management of early sepsis may be effective in one context [2] but not another [3] . Demonstrating external validity is therefore particularly important for many therapies in intensive care medicine.
Clinical trials in intensive care tend to enrol a variety of different patients. As it is reasonable to expect that the efficacy of many treatments will be influenced by factors such as underlying diagnosis, severity of illness, comorbidity and age, many trials attempt separate analyses of these subgroups. The SAFE study of albumin versus saline in critical illness employed subgroup analysis [4] , finding that while overall albumin was 'safe', its use was associated with increased mortality in the subset of patients with traumatic brain injury [5] . As the total number of patients in each trial is conventionally determined by the desire for an 80 or 90% chance of finding a difference if one is present, such subgroup analyses are invariably underpowered. A method to enhance the power of subgroup analyses would be a valuable tool in intensive care research.
Meta-analysis of trials performed in a variety of contexts is a powerful means of assessing external validity. By pooling trial results, meta-analysis can also facilitate adequately powered exploration of subgroup effects. However, a number of meta-analytic conclusions in intensive care medicine [6] [7] [8] have subsequently been disproven by adequately powered RCTs, serving as one explanation for why many physicians shun the recommendations of traditional meta-analyses [9, 10] . Many factors influence the conclusion of a meta-analysis, including publication bias, selection of measures of effect [11] , the need to appropriately define study inclusion and exclusion criteria, and the methods chosen to account for missing data and for clinical and statistical heterogeneity. Such considerations are paramount, regardless of the statistical method selected. However, in addition, there is a potential for misleading conclusions if a meta-analysis is conducted without using all of the data of the constituent trials. This potentially applies more in intensive care medicine than in other fields, given the significant heterogeneity of patients and intercurrent treatments within each trial. In this review, we examine the limits of traditional meta-analysis and outline a method, particularly relevant to intensive care medicine, by which this problem can be overcome.
Types of meta-analysis
There are two types of meta-analyses: those using aggregate data and those based on data from individual patients. Aggregate data are obtained from published reports, which may be supplemented using associated unpublished data if this is supplied by the authors. On some occasions, aggregate meta-analyses also incorporate data from unpublished studies, again in collaboration with the trialists. Aggregate data are easier to obtain and more frequently used [12, 13] .
While the meta-analysis of aggregate patient data is often appropriate, it can be misleading [14, 15] : for example, the 1998 Cochrane meta-analysis that associated albumin use in critically ill patients with a 6% increase in mortality [7] . Using only aggregate data, this analysis could not adequately account for important patient, treatment and contextual heterogeneity across included trials [16, 17] . A subsequent large (n = 6,997) multicentre, double-blinded RCT did not confirm this increased mortality [4] . The reasons for this discordance are outlined below.
Heterogeneity in meta-analysis
Accounting for differences in constituent studies can be the largest analytic challenge when pooling results. Heterogeneity among trials is classified into trial-level differences, which apply to all of the patients in each individual trial (the classic example being dose of a drug), and patient-level differences (for example, age), where the characteristic varies both within and between trials.
A small degree of between-trial heterogeneity can be accounted for using a random-effects, as opposed to a fixed-effects, statistical model. A random-effects model does not assume all trials estimate the same intervention effect, allowing the possibility of different effects under different circumstances, which reduces the precision of the treatment effect estimate. A disadvantage of random effects models is the disproportionate weight they accord to small studies, which may be more likely to provide biased estimates of treatment effect due to selection bias or poor methodological quality [18] . An empirical study of 84 published meta-analyses [18] found 9 examples in which a fixed-effects model identified a significant treatment effect where a random-effects model did not [18] . Selecting the appropriate statistical model should be driven by nature of the studies, a process facilitated by knowledge of the individual patient data (IPD).
Exploring trial level heterogeneity: subgroup meta-analysis and meta-regression Understanding differences in the conduct of trials can provide important information, and mathematical corrections for such variation may be undesirable. For example, if a drug benefits men but is harmful for women, knowing this is preferable to using a single summary statistic concluding overall moderate advantage. The two approaches that take advantage of trial-level heterogeneity, rather than correcting for it, are subgroup meta-analysis and, in the case where groups can be placed on an interval scale, metaregression.
Subgroup meta-analysis examines the effect of a potential confounding factor by splitting data from constituent trials according to category. Such analyses must be interpreted with care. Consider various trials of a drug, some of which use the oral and some the intravenous route. Conducting separate meta-analyses on each of these strata makes intuitive sense. However, comparisons of the difference in effect due to route of administration may be misleading. If mortality is less with the oral route, it is tempting to conclude that the oral route is superior, but the possibility of confounding (for example, perhaps patients who could use the oral route were less ill) makes such a naïve comparison unwise. Furthermore, independently testing whether there is a treatment effect in separate subgroups, such as men and women, does not address the question of whether treatment differences vary by sex. Rather, a statistical test of the significance of the interaction of the subgroup and treatment effects in a multivariable model is required [19] . Statistical methods for dealing with indirect comparisons of treatment effect are still evolving [20, 21] .
When a potential confounding factor can be expressed on an ordinal scale, an extension of subgroup metaanalysis is metaregression [22] . Meta-regression is a statistical test of the effect of one or more characteristics of each of the included studies (such as drug dose) on the estimate of the overall effect. As is true in a multivariable subgroup model, meta-regression is most useful when there is a clear treatment effect, a large number of studies, sufficient between-trial variation in the postulated confounding variable, and sufficient heterogeneity among the treatment effects [15] . Larger studies with more precise estimates carry greater weight. A meta-regression is often presented in graphical form, as in Fig. 1 .
The main criticism of splitting trials into many subgroups is that this increases the probability of erroneous conclusions due to the statistical problem of multiple comparisons. At the same time, the small number of trials on which most meta-regression analyses are based limits power, so true associations may be missed [23] .
Exploring patient level heterogeneity: avoiding the ecological fallacy using individual patient data Meta-regression of aggregate data is problematic when examining heterogeneity at the patient level. Such an analysis must use averages of patient characteristics within each trial, but the relationship between the effect estimate and average patient characteristics across trials may not be the same as the relationship for patients within trials, as demonstrated in Fig. 2 . This is the 'ecological fallacy' described in observational studies, in which spurious inferences about individual characteristics are made based upon aggregate statistics for the group to which those individuals belong. Examining individual patient data can help to avoid this fallacy in meta-analysis [24] . IPD meta-analysis is based on a reanalysis of treatment effects and potential confounders using data from each patient. The process differs from a multi-centre study in that trials need not use identical protocols, but they must be sufficiently similar to allow statistical adjustment for the effect of covariates such as drug dose and patient illness severity. While protocols need not be identical, the analysis is facilitated if data collection is harmonised. Fig. 1 a Meta-regression analysis (reproduced with permission from [22] , based on data in [78] ) showing no effect of aspirin dose on risk of stroke. b Meta-regression analysis (reproduced with permission from [79] ) showing a dose-response effect of low molecular weight heparin on risk of asymptomatic proximal deep venous thrombosis. In each case, log relative risk (relative to placebo) is plotted according to dose, together with a summary random-effects meta-regression. The area of each circle is inversely proportional to the variance of the log relative risk estimate
Advantages of using individual patient data for meta-analysis
Simplistically, statistical significance is determined by the ratio of 'explained' to 'unexplained' variation. Incorporation of individual patient covariates, treatment differences between studies and the interactions of these factors accounts for a greater proportion of the 'unexplained' variation than does analysis of mean values for patient characteristics and trial differences. Controlling for confounding factors at an individual level facilitates a more accurate determination of statistical significance, a feature confirmed in a data-simulation study [14] . It also avoids the ecological fallacy.
Other advantages of IPD meta-analyses over those using aggregate patient data (Table 1) include the ability to undertake sufficiently powered subgroup analyses, update survival information, carry out a detailed check of the primary data, check the statistical assumptions of regression models, reanalyse the data using intention to treat (if this is appropriate to the situation), include patients excluded from the original analyses, [25] and better adjust for underlying risk [26] . The ability of an IPD meta-analysis to analyse time to event data rather than single point outcome statistics (e.g., 28-day mortality) has been empirically shown to improve the precision of effect estimates [27] . Admittedly, if time to event data are available from the constituent trials, techniques are evolving to allow this to be considered in an aggregate data meta-analysis [28] . If such data are not available it can sometimes be inferred [29] , but if only landmark endpoints are reported even inference is not possible. For all these reasons, using individual patient data is acknowledged by the Cochrane Collaboration as 'the gold standard methodology for carrying out a meta-analysis' [30] .
Comparisons of conclusions based on aggregate and IPD meta-analyses
The advantage of IPD over aggregate data in meta-analysis might best be demonstrated by analysis of the same data using both techniques. In the examples identified in the intensive care literature, this proved impossible when reliant on only published material: analyses often contained unpublished data, patient characteristics or outcome measures that were not reported in the original papers, or such a small number of studies were quoted that an aggregate data meta-analysis would have little meaning.
Authors in other specialties have attempted to compare the two meta-analytic techniques. Several of these [31] [32] [33] [34] [35] [36] [37] are not fair comparisons, as the two meta-analytic techniques were applied to different datasets. Six examples of comparisons using the same data are listed in Table 2 . On each occasion, divergent results have been Fig. 2 The ecological fallacy in meta-regression (reproduced with permission from [22] ). Hypothetical relationships between age and treatment effect both within trials (represented by lines) and between trials (represented by dots). In the upper graph, treatment effect consistently varies with age within each trial, but this relationship is not apparent when the mean ages from each trial are plotted against effect. Conversely, an aggregate meta-analysis using data in the lower graph would conclude (mean) age determines treatment effect, whereas this is seen to be not true when data from individual patients is taken into account. The misleading relationship between average age and treatment effect in this lower graph could be due to some confounding factor associated with average age, such as wealth, that varies between the studies [35, 38, 39] ), to be sure of this it is necessary either to undertake the IPD analysis, or to be certain of the absence of confounding. Given the patient-level heterogeneity typical of intensive care trials, such certainty is unlikely to be present in our field. A protocol for systematically comparing meta-analyses of IPD with those of aggregate data has been proposed by the Cochrane Collaboration [40] , but as yet this has not been performed.
Statistical issues in IPD meta-analysis
Statistical techniques used for IPD meta-analysis are developing [41] [42] [43] . The simplest is to combine all of the individual patient data as if they came from a single large trial (e.g., [44] ). Most agree this is a flawed approach, analogous to analysing a cluster RCT without taking into account the statistical aberration caused by the tendency of patients from the same centre to be similar. Better approaches incorporate information that patients were part of a particular trial as part of a multiple regression ('onestage') analysis or adopt a 'two stage' approach where studies are reanalysed separately, then combined using standard aggregate data meta-analytic techniques. The one-stage approach offers more flexibility in modelling the effects of potential confounders, allowing appropriate treatment of random and fixed effects study-and patientlevel covariates by using mixed linear models or generalised estimating equation (GEE) models. Despite this, until now the 'two stage' IPD meta-analytic method has been more common [7] , perhaps because it is more easily understood by clinicians.
Almost all clinical studies must decide on an approach to missing data. A simple option is complete case analysis-entirely removing subjects with a missing value-but this typically reduces precision and introduces bias. Better approaches include single imputation, in which subjects with complete data are used to estimate the distribution of the missing variables, from which the missing values are randomly selected, and multiple imputation, in which this process is repeated a number of times such that the randomly selected value better reflects the distribution from which it is drawn. Unfortunately, the extent of missingness often varies between studies, creating a problem when they are combined in an IPD meta-analysis. Imputation in IPD meta-analysis can be performed within the dataset of each trial, before pooling, or in the final dataset after pooling. Imputation after pooling allows estimation of entire variables that were not collected in one or more of the trials. Imputation before pooling is required in the two-stage technique (described above), but is potentially less powerful in the (preferred) one-stage technique. However, imputation after pooling can result in bias if the association The aggregate data approach detected a different treatment effect in a subgroup (characterised by their time from first seizure) not identified in the IPD meta-analysis. The conclusion of the aggregate analysis was considered spurious, an effect of multiple testing Berlin et al. [24] 628 patients from 5 trials
Trials of anti-lymphocyte antibody for the prevention of allograft failure in renal transplantation
Aggregate data meta-regression failed to detect the importance of a patient level characteristic (level of panelreactive-antibody), whereas IPD meta-analysis found this was a significant modifier of treatment effect Schmid et al. [15] 1,860 patients from 11 trials
Angiotensin converting enzyme inhibitors for nondiabetic renal disease
Only the IPD meta-analysis found treatment reduced renal function in the subgroup of patients with higher proteinuria at baseline Koopman et al. [62] 1,643 patients from 6 trials Antibiotics for otitis media Aggregate meta-analysis of the two studies to report effect in age-defined subgroups produced different estimates of effect size than did the IPD meta-analysis Barton [63] 7,686 patients from 4 trials
Risedronate for the modification of fracture risk
Only IPD meta-analysis detected a bone density threshold beyond which treatment had little effect on fracture risk between variables in one study is different to that in another. The optimal approach is, to a degree, a matter of opinion. However, following an empirical study that showed marked differences in the results obtained, a recent recommendation is that imputation within trials is the preferred approach [45] , sacrificing higher power for the benefit of less bias.
Disadvantages of IPD meta-analysis
IPD meta-analyses do not solve all of the problems present in analyses using aggregate patient data. Poor quality constituent studies-in terms of design or conduct-will be equally problematic. The accuracy of the individual patient data usually depends on the original trial; rarely will it be possible for the IPD meta-analysts to make anything other than checks for logical inconsistencies. While offering greater potential to correct for study heterogeneity at the patient level, trials must still be sufficiently similar. Unmeasured confounding factors cannot be incorporated into any analysis, so heterogeneity may remain an unrecognised problem. Furthermore, by excluding unavailable patient-level data, retrospective IPD meta-analyses potentially introduce an additional study selection bias. A sensitivity analysis can help mitigate this, using aggregate data from the trials that did not contribute to the IPD meta-analysis [34, 46] . Inclusion bias should be suspected if inclusion of aggregate data substantially alters the results, although the quality of the additional information must also be assessed. The use of unpublished information risks degraded data quality due to unrecognised crossover, unblinding and missing data [47] . Statistical techniques are evolving to allow incorporation of aggregate data into the IPD analysis [48] .
Barriers to the conduct of IPD meta-analysis
The main obstacle in conducting an IPD meta-analysis is access to the data. Data may be unavailable if they were destroyed by the investigators, or if the study team no longer exists. Investigators may be unwilling to allow their data to be used in subgroup analyses that they might wish to perform themselves. There may be mistrust in the ability of others to manipulate data and conduct statistical modelling. The meta-analysis may contradict the results of one of the original studies, diminishing its importance. If the metaanalysis becomes the definitive contribution to the field, the prominence of the original investigators may be lessened. Equally, there may be competing commercial interests. Even if investigators are willing and able to share their data, requirements for patient confidentiality may impede access, especially if this involves sending information to another country with different privacy laws. If required information is unrecorded at the time of the original study, it is usually impractical to obtain it later. This is true of potential confounders and also of outcome measures such as the times at which mortality is assessed. IPD metaanalyses therefore require a planned, collaborative effort between authors of the constituent studies, and a commitment to extract as much benefit as possible from trial data.
Individual patient data meta-analyses in intensive care medicine IPD meta-analyses have been performed in intensive care medicine, albeit infrequently. Examples of IPD metaanalyses in intensive care medicine are summarised in Table 3 .
Optimal IPD meta-analysis requires a detailed methodological description. Ideally, hypotheses and methods should be articulated in advance, as is the case in the proposed IPD meta-analysis of high-frequency oscillatory ventilation in preterm infants with respiratory distress syndrome [49] . A criticism of many meta-analyses, especially those using IPD, is lack of clear reporting. It can be impossible to reconstruct analyses if unpublished data are used but poorly cited or reported. This criticism appears valid in IPD meta-analyses in intensive care. For example, the analysis by Mauer et al. [46] does not specifically cite any of the included studies, and incorporates two unpublished studies from 'Brussels' and 'Thessaloniki' that are not further identified. Similarly, the analytic approaches chosen by D'Amico et al. [34] and Holzer et al. [50] are not stated, although Holzer et al. offer to provide such details 'on request'. Unfortunately, neither the relevant Cochrane guidelines [51] nor the QUOROM guidelines specifically address the ideal reporting of IPD meta-analysis [52] .
Prospective meta-analysis
By planning a meta-analysis before trials commence, many of the listed barriers can be overcome. Hypotheses and intended analytic techniques for sub-group analyses can be specified in advance, and randomisation may even be stratified by subgroups relevant to the meta-analysis but of less interest to one or more of the constituent trials. Advantages of a prospective design include consistent entry criteria, study protocols and outcome measures, consistent data collection, and avoiding the criticism of 'data dredging' [53] .
A prospective meta-analysis must be designed with the same rigour as a clinical trial. It should be entered in an independent registry (such as that maintained by the Cochrane Collaboration [53] ) from the outset. Some prospective meta-analyses are conducted over decades (see below), with new trials adding to the growing data pool. In such cases they should consider a data safety monitoring protocol, with formal stopping rules for effect and harm [54] . However, this is potentially problematic: if the meta-analysis is terminated early, there is little precedent to guide the responses of investigators in trials still underway. There may be understandable reluctance to agree to a process whereby the results from other trials, over which they have no control, may dictate early termination of a study group's effort. Early termination of trials is a recognised problem [55] . The context-dependence of [57] , investigated the effect of cholesterol lowering agents [58] and evaluated treatments in subgroups of children with acute lymphoblastic leukaemia [59] . Many published reports describe the planning of prospective meta-analyses that have not yet been reported, perhaps highlighting the difficulty of putting good intentions into practice.
Conclusions
Far from being an obscure point of statistical methodology, the above discussion suggests sub-group metaanalyses based on IPD should be accorded a higher grade of evidence than those based on only aggregate data.
However, despite strong theoretical arguments, the empirical evidence supporting this position is limited. Only six studies [15, 24, [60] [61] [62] [63] have directly compared the two techniques using the same data, finding clinically significant effects of only a limited number of covariates. Nonetheless, we suggest that the potential effect of variations in baseline risk and intercurrent care is sufficiently large in intensive care to threaten the validity of any metaanalysis based on aggregate data.
Implications
There are immediate opportunities to employ IPD MA in intensive care medicine. Large, multicentre trials of the intensity of renal replacement (the ATN [64] and RENAL [65] studies) and of intensive insulin therapy (NICE-SUGAR [66] , Glucontrol [67] and VISEP [68] ) have been completed. Trials of Early Goal Directed Therapy (EGDT) for severe sepsis [the Protocolized Care for Early Septic Shock (ProCESS) [69] and the Australian Resuscitation in Sepsis Evaluation (ARISE) [70] studies] are in their early stages, and a similar trial (Protocolised Management In Sepsis: ProMISe) will soon commence in the UK. For each clinical question, while each trial is adequately powered to detect an effect of the treatment protocol if one exists, none may be able to answer questions such as 'Does one type of patient benefit more?' or 'In which type of hospital is the intervention most effective'? The best chance of increasing the total power of these studies and of finding important subgroup effects is by IPD meta-analysis. We propose the use of IPD MA as a new chapter in the application of evidence based medicine to intensive care.
